Correlated Drug Terms (1)

---

	Name (Synonyms)	Correlation
drug1822	Placebo Wiki	0.06

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Disease progression is defined by the development of need for mechanical ventilation or death. Mechanical ventilation includes CPAP, BIPAP or mechanical ventilation requiring intubation.

Measure: Proportion of participants with disease progression from randomization to 28 days post-randomization

Time: 28 days

---

Secondary Outcomes

Measure: Proportion of participants with all-cause mortality

Time: 28 days

---

Measure: Proportion of participants who transfer to ICU level care by Day 28 (ICU level care is defined as a hospital setting where patient to nurse ratio is < 4);

Time: 28 days

---

Measure: Proportion of participants with a new onset of neurologic disease (requiring medical intervention), including stroke by Day 28;

Time: 28 days

---

Measure: Proportion of participants with evidence of new CHF or new MI requiring medical intervention by Day 28;

Time: 28 days

---

Measure: Proportion of participants with a new onset embolus or thrombus by Day 28;

Time: 28 days

---

Measure: Proportion of participants who develop a need for renal replacement therapy (defined as need for any type of dialysis including intermittent or continuous peritoneal or hemodialysis) by Day 28;

Time: 28 days

---

Measure: Proportion of participants with an increase in the WHO Ordinal Scale of Clinical Improvement score at any time during the study;

Time: 28 days

---

Measure: Length of hospital stay defined as the number of days in hospital from time of randomization to time of discharge or death, whichever occurs first;

Time: 28 days

---

Measure: Change from baseline in inflammation markers over time.

Time: 28 days

---

Other Outcomes

Measure: Incidence of adverse events and serious adverse events not due to underlying disease

Time: 28 days

---

Measure: Incidence of abnormal findings in clinical safety laboratory parameters, vital signs, and ECGs.

Time: 28 days

---